Features of CLOCC syndrome in the patient b-lymphoblastic lymphoma. A case report
A. Yu. Terekhova,
A. B. Galitsyna,
A. M. Chelmakov,
N. A. Falaleeva,
V. A. Shuvaev,
A. A. Danilenko,
M. M. Geraskina,
T. A. Agababyan,
V. O. Ripp,
D. A. Manaenkov,
S. A. Ivanov https://doi.org/10.21294/1814-4861-2025-24-2-169-176
Abstract
Introduction. Cytotoxic corpus callosum syndrome (CLOCC syndrome) is a rare neurological pathology, the pathogenesis of which has not been fully studied. The CLOCC syndrome, which develops in cancer patients, is a serious concomitant pathology that complicates anti-cancer treatment. Description of the clinical case. A 34 year-old female patient was admitted to the A. F. Tsyba MRRC in August 2023 with a diagnosis of stage IV plasmoblastic lymphoma established at her place of residence. Taking into account the severity of the patient’s disease, EPOCH chemotherapy with intrathecal administration of cytostatics was immediately initiated to prevent neuroleukemia. Infectious complications (febrile neutropenia and enterocolitis) that developed during therapy caused neurological disorders, which together with MRI findings, were assessed as CLOCC syndrome. These changes regressed over several days during desmopressin treatment and massive dehydration therapy with crystalloid and glucose solutions. Histological re-examination of the first biopsy specimen and immunohistochemical studies revealed B-lymphoblastic lymphoma, which led to a correction of the further therapy plan. Conclusion. The cause of the development of CLOCC syndrome in this patient can be assumed to be a combination of the damaging effects of cytostatics on brain tissue and electrolyte imbalance.
About the Authors
A. Yu. Terekhova
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia ; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Russian Federation
Russian Federation
Alyona Yu. Terekhova, MD, PhD, Senior Researcher, Department of Radiation and Drug Treatment of Hemoblastosis; Associate Professor, Department of Internal Medicine
10, Marshal Zhukov St., Obninsk, 249031
1, Studgorodok, Obninsk, 249039
A. B. Galitsyna
Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Russian Federation
Russian Federation
Anastasia B. Galitsyna, student, Faculty of Medicine
1, Studgorodok, Obninsk, 249039
A. M. Chelmakov
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia
Russian Federation
Russian Federation
Andrey M. Chelmakov, MD, Hematologist, Department of Radiation and Drug Treatment of Hemoblastosis
10, Marshal Zhukov St., Obninsk, 249031
N. A. Falaleeva
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia ; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Russian Federation
Russian Federation
Natalia A. Falaleeva, MD, DSc, Head of the Departments of Antitumor Drug Treatment of Malignant Neoplasms; Professor, Department Internal Medicine
10, Marshal Zhukov St., Obninsk, 249031
1, Studgorodok, Obninsk, 249039
V. A. Shuvaev
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia ; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Russian Federation
Russian Federation
Vasily A. Shuvaev, MD, DSc, Head of the Department of Radiation and Drug Treatment of Hemoblastosis; Professor, Department of Internal Medicine; Professor, I.A. Kassirsky and A.I. Vorobyov Department of Hematology and Transfusiology, Russian Academy of Medical Sciences
10, Marshal Zhukov St., Obninsk, 249031
1, Studgorodok, Obninsk, 249039
A. A. Danilenko
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia
Russian Federation
Russian Federation
Anatoly A. Danilenko, MD, DSc, Senior Researcher, Department of Radiation and Drug Treatment of Hemoblastosis
10, Marshal Zhukov St., Obninsk, 249031
M. M. Geraskina
Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI” ; Clinical Hospital No. 8 of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Maria M. Geraskina, MD, PhD, Associate Professor, Department of Internal Diseases; Head of the Department of Neurology
1, Studgorodok, Obninsk, 249039
85, Lenin Ave., Obninsk, 249032
T. A. Agababyan
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia ; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Russian Federation
Russian Federation
Tatev A. Agababyan, MD, PhD, Associate Professor, Department of Radionuclide Medicine; Head of the Department of Radiation Diagnostics
10, Marshal Zhukov St., Obninsk, 249031
1, Studgorodok, Obninsk, 249039
V. O. Ripp
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia
Russian Federation
Russian Federation
Vladislav O. Ripp, MD, Radiologist, Department of Radiation Diagnostics
10, Marshal Zhukov St., Obninsk, 249031
D. A. Manaenkov
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia
Russian Federation
Russian Federation
Daniil A. Manaenkov, MD, Oncologist, Department of Bone Marrow Transplantation
10, Marshal Zhukov St., Obninsk, 249031
S. A. Ivanov
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia ; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Russian Federation
Russian Federation
Sergey A. Ivanov, MD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Director; Professor, Department of Radionuclide Medicine
10, Marshal Zhukov St., Obninsk, 249031
1, Studgorodok, Obninsk, 249039
References
1. Filippi C.G., Cauley K.A. Lesions of the corpus callosum and other commissural fibers: diffusion tensor studies. Semin Ultrasound CT MR. 2014; 35(5): 445–58. doi: 10.1053/j.sult.2014.06.004.
2. Kim S.S., Chang K.H., Kim S.T., Suh D.C., Cheon J.E., Jeong S.W., Han M.H., Lee S.K. Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? Am J Neuroradiol. 1999; 20(1): 125–29
3. Oster J., Doherty C., Grant P.E., Simon M., Cole A.J. Diffusionweighted imaging abnormalities in the splenium after seizures. Epilepsia. 2003; 44(6): 852–54. doi: 10.1046/j.1528-1157.2003.40902.x.
4. Maeda M., Shiroyama T., Tsukahara H., Shimono T., Aoki S., Takeda K. Transient splenial lesion of the corpus callosum associated with antiepileptic drugs: evaluation by diffusion-weighted MR imaging. Eur Radiol. 2003; 13(8): 1902–6. doi: 10.1007/s00330-002-1679-5.
5. Takahashi I., Yano H., Kinjo M. Mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) following influenza virus infection. BMJ Case Rep. 2020; 13(5). doi: 10.1136/bcr-2020-235461.
6. Karampatsas K., Spyridou C., Morrison I.R., Tong C.Y., Prendergast A.J. Rotavirus-associated mild encephalopathy with a reversible splenial lesion (MERS)-case report and review of the literature. BMC Infect Dis. 2015; 15: 446. doi: 10.1186/s12879-015-1192-5.
7. Miller A.H., Haroon E., Raison C.L., Felger J.C. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013; 30(4): 297–306. doi: 10.1002/da.22084.
8. Berczi I., Szentivanyi A., editors. Neuroimmune Biology. (Christopher P. Phelps, Elena A. Korneva, editors. Cytokines and the Brain; vol. 6. Amsterdam: Elsevier Science; с2008. 575 p. ISBN: 9780444530417).
9. Leonoudakis D., Braithwaite S.P., Beattie M.S., Beattie E.C. TNFalpha-induced AMPA-receptor trafficking in CNS neurons; relevance to excitotoxicity? Neuron Glia Biol. 2004; 1(3): 263–73. doi: 10.1017/S1740925X05000608.
10. Kim Y.S., Honkaniemi J., Sharp F.R., Täuber M.G. Expression of proinflammatory cytokines tumor necrosis factor-alpha and interleukin- 1beta in the brain during experimental group B streptococcal meningitis. Brain Res Mol Brain Res. 2004; 128(1): 95–102. doi: 10.1016/j.molbrainres.2004.06.009.
11. Prow N.A., Irani D.N. The inflammatory cytokine, interleukin-1 beta, mediates loss of astroglial glutamate transport and drives excitotoxic motor neuron injury in the spinal cord during acute viral encephalomyelitis. J Neurochem. 2008; 105(4): 1276–86. doi: 10.1111/j.1471-4159.2008.05230.x.
12. Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012; 76(1): 16–32. doi: 10.1128/MMBR.05015-11.
13. Andersen J.V. The Glutamate/GABA-Glutamine Cycle: Insights, Updates, and Advances. J Neurochem. 2025; 169(3). doi: 10.1111/jnc.70029.
14. Moritani T., Smoker W.R., Sato Y., Numaguchi Y., Westesson P.L. Diffusion-weighted imaging of acute excitotoxic brain injury. Am J Neuroradiol. 2005; 26(2): 216–28.
15. Castiglione J.I., Ricciardi M.E., Bensi C. Cytotoxic lesion of the corpus callosum in a patient with aphasic status epilepticus. J Applied Cognitive Neuroscience. 2020; 1(1): 98–100. doi: 10.17981/JACN.1.1.2020.15.
16. Turtzo L.C., Luby M., Jikaria N., Griffin A.D., Greenman D., Bokkers R.P.H., Parikh G., Peterkin N., Whiting M., Latour L.L. Cytotoxic Edema Associated with Hemorrhage Predicts Poor Outcome after Traumatic Brain Injury. J Neurotrauma. 2021; 38(22): 3107–18. doi: 10.1089/neu.2021.0037.
17. Xu Z., Zhou Z., Jang W., Tian J., Hou G. Reversible splenial lesion syndrome with mental disorders as only manifestation. BMC Neurol. 2021; 21(1): 356. doi: 10.1186/s12883-021-02391-6.
18. Renard D., Bonafe A., Heroum C. Transient lesion in the splenium of the corpus callosum after oral corticoid therapy. Eur J Neurol. 2007; 14(8): 19–20. doi: 10.1111/j.1468-1331.2007.01872.x.
19. Butterworth R.F. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure. J Clin Exp Hepatol. 2015; 5(s1): 96–103. doi: 10.1016/j.jceh.2014.02.004.
20. Orhan Varoglu A., Avarisli A., Keskin H., Darici D. The risk factors affecting the persistence of corpus callosum splenium lesions. Acta Radiol. 2024; 65(9): 1101–8. doi: 10.1177/02841851241267147.
21. Jayakumar A.R., Rama Rao K.V., Norenberg M.D. Neuroinflammation in hepatic encephalopathy: mechanistic aspects. J Clin Exp Hepatol. 2015; 5(Suppl 1): 21–28. doi: 10.1016/j.jceh.2014.07.006.
22. Rocchi A., Sariyer I.K., Berger J.R. Revisiting JC virus and progressive multifocal leukoencephalopathy. J Neurovirol. 2023; 29(5): 524–37. doi: 10.1007/s13365-023-01164-w.
23. Tetsuka S. Reversible lesion in the splenium of the corpus callosum. Brain Behav. 2019; 9(11). doi: 10.1002/brb3.1440.
24. Park M.K., Hwang S.H., Jung S., Hong S.S., Kwon S.B. Lesions in the splenium of the corpus callosum: Clinical and radiological implications. Neurology Asia. 2014; 19(1): 79–88.
25. Förster A., Apfaltrer P., Al-Zghloul M., Wenz H., Alonso A., Groden C. Diffusion Restricted Lesions in the Splenium of the Corpus Callosum. In Vivo. 2022; 36(3): 1354–59. doi: 10.21873/invivo.12838.
26. Aoshima M., Nagayama K., Takeshita K., Ajima H., Orikasa S., Iwazaki A., Takatori H., Oki Y. Methotrexate-associated lymphoproliferative disorder with hypopituitarism and central diabetes insipidus. Endocrinol Diabetes Metab Case Rep. 2019. doi: 10.1530/EDM-19-0082
Review
For citations:
Terekhova A.Yu., Galitsyna A.B., Chelmakov A.M., Falaleeva N.A., Shuvaev V.A., Danilenko A.A., Geraskina M.M., Agababyan T.A., Ripp V.O., Manaenkov D.A., Ivanov S.A. Features of CLOCC syndrome in the patient b-lymphoblastic lymphoma. A case report. Siberian journal of oncology. 2025;24(2):169-176. (In Russ.) https://doi.org/10.21294/1814-4861-2025-24-2-169-176
Views:
1058
Email this article 
